Lung Cancer Diagnostics Market, Size, Global Forecast 2024-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Companies Analysis

Global Lung Cancer Diagnostics Market is predicted to be valued at around US$ 30.84 Billion by 2030. In modern-day healthcare, lung cancer diagnostics are pivotal in early detection and personalized treatment. Advanced imaging strategies like CT scans and MRI permit particular identification of tumors and metastases, assisting in staging and treatment planning. Biomarker testing, inclusive of genetic mutations and protein expression analysis, allows for centered remedies tailor-made to their patients, improving results and minimizing side effects. Further, liquid biopsies offer a non-invasive tracking of disease progression and remedy responses. With non-stop improvements in technology and research, lung cancer diagnostics continue to conform, offering a want for improved survival rates and standard of life.

Global Lung Cancer Diagnostics Market is predicted to increase at a CAGR of 7.23% during the projection period (2024 to 2030)

The demand for superior lung cancer diagnostics has improved because of the rising prevalence of the disease globally. According to the Lung Cancer Research Foundation, smoking is the dominating risk element for lung cancer, accounting for 80% of lung cancer deaths. In comparison, individuals who've in no way smoked account for the remaining 20% of lung cancer deaths. Early detection techniques enhance patient outcomes, including imaging technology and biomarker testing. The global lung cancer diagnostics market is expanding unexpectedly as healthcare systems prioritize screening programs and access to diagnostic equipment. Increased investments in studies, progressive technology, and customized remedy approaches fuel an increase in coping with prevailing diseases.

Adopting multimodal diagnostic procedures is revolutionizing the global lung cancer diagnostics market. Clinicians gain broad insights into tumor characteristics and staging by integrating diverse imaging modalities like CT, PET, and MRI alongside molecular and genetic analyses. This approach complements accuracy in prognosis and treatment planning, driving the growth of the cancer diagnostics market. With increasing recognition of the importance of early detection and personalized medicinal drugs, the demand for multimodal diagnostic solutions continues to push upward, shaping the landscape of lung cancer diagnostics worldwide. Hence, the global lung cancer diagnostics market was US$ 18.92 Billion in 2023.

The North America lung cancer diagnostic market has witnessed considerable expansion. This is fueled by adopting contemporary technology and a resilient healthcare infrastructure. As a beacon of innovation, it sets standards for diagnostic excellence, spurring worldwide demand. Moreover, ongoing studies and improvement endeavors, specifically in early cancer detection, promise to elevate the lung cancer diagnostic and screening market worldwide, reinforcing its pivotal role in preventing this pervasive sickness worldwide.

One of the most critical areas of the lung cancer diagnostics market worldwide is imaging tests

By diagnosis test type, the global lung cancer diagnostics market is fragmented into Imaging Tests, Biopsy, Sputum Cytology, Molecular Tests, and Others. Imaging tests stand among the forefront sections of the global lung cancer diagnostics market. This is due to their pivotal function in early detection and correct assessment of tumors. Technologies like computed tomography (CT), positron emission tomography (PET), and magnetic resonance imaging (MRI) offer specified visualization of lung tissue, helping in tumor localization, staging, and remedy planning. Their non-invasive nature and capability to stumble on abnormalities at early phases contribute to their recognition. Imaging assessments are vital in lung cancer diagnosis, thanks to non-stop technological improvements that enhance resolution and specificity. This has solidified their function as a leading section in the worldwide market.

Non-Small Cell Lung Cancer is among the most significant elements in the global lung cancer diagnostics market

The global lung cancer diagnostics market is split by cancer type into non-small and small-cell lung cancer. Non-Small Cell Lung Cancer (NSCLC) holds one of the prominent positions in the global lung cancer diagnostics market. This is due to its high incidence and numerous treatment alternatives. NSCLC drives considerable demand for diagnostic assessments, which include imaging, biomarker evaluation, and histopathology. Its heterogeneous nature necessitates a precise prognosis and staging for top-quality remedy choice, spurring innovation in diagnostic technology. Moreover, advancements in centered treatments and immunotherapies tailor-made to particular NSCLC subtypes further underscore the importance of correct diagnosis. As NSCLC continues to pose a substantial healthcare burden, its diagnostic stage remains a cornerstone of the global lung cancer diagnostics market.

Hospital Associated Labs are integral to the global lung cancer diagnostics market

By end-user, the global lung cancer diagnostics market is categorized into Hospital Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, and Others. Hospital Associated Labs is one of the most used in the global lung cancer diagnostics market. This is due to their accessibility and comprehensive services. Situated in healthcare centers, these labs offer short turnaround times for diagnostic tests, including imaging, biopsies, and molecular analyses. Their close collaboration with clinicians facilitates seamless patient care, making them a preferred choice for accurate and well-timed lung cancer analysis and treatment planning.

United States may continue to maintain its lead in the global market for lung cancer diagnostics

By country, the global lung cancer diagnostics market is divided into North America (United States, Canada), Europe (France, Germany, Italy, Spain, United Kingdom, Belgium, the Netherlands, and Turkey), Asia Pacific (China, Japan, India, Australia, South Korea, Thailand, Malaysia, Indonesia, and New Zealand), Latin America (Brazil, Mexico, and Argentina), Middle East & Africa (South Africa, Saudi Arabia, and the UAE). The United States might stay dominant in the global lung cancer diagnostics market. This is pushed by the increasing occurrence of neurological disorders, contributing to improving the area's lung cancer diagnostics market.

For example, in line with a record by the American Society of Clinical Oncology (ASCO) in 2023, 81% of all lung cancer diagnoses in the United States were non-small cell lung cancers (NSCLC). Moreover, the United States has a sturdy healthcare system with advanced diagnostic tools, most lung cancer cases, and a focus on early detection and customized medication. It invests closely in R&D, propelling innovation and setting global lung cancer diagnosis standards.

Key Players

The global lung cancer diagnostics market comprises of leading companies like llumina, Abbott Laboratories, Thermo Fisher Scientific, Inc, QIAGEN N.V., Roche Holding AG., Sanofi S.A., Agilent Technologies, and bioMérieux.

In October 2023 - DELFI Diagnostics recently announced the launch of FirstLook Lung, a blood-based test that provides a new and more accessible way to detect lung cancer. This test offers a convenient, accurate, and personalized result by determining the likelihood of detecting lung cancer through low-dose CT (LDCT) with a negative predictive value (NPV) of 99.7 percent.

Diagnosis Test Type - Market breakup in 5 viewpoints:

1. Imaging Test
2. Biopsy
3. Sputum Cytology
4. Molecular Test
5. Others

Cancer Type - Market breakup in 2 viewpoints:

1. Non- Small Cell Lung Cancer
2. Small Cell Lung Cancer

End-User - Market breakup in 5 viewpoints:

1. Hospital Associated Labs
2. Independent Diagnostic Laboratories
3. Diagnostic Imaging Centers
4. Cancer Research Institutes
5. Others

Country - Market breakup in 25 Countries:

1. North America
1.1 United States
1.2 Canada
2. Europe
2.1 France
2.2 Germany
2.3 Italy
2.4 Spain
2.5 United Kingdom
2.6 Belgium
2.7 Netherlands
2.8 Turkey
3. Asia Pacific
3.1 China
3.2 Japan
3.3 India
3.4 South Korea
3.5 Thailand
3.6 Malaysia
3.7 Indonesia
3.8 Australia
3.9 New Zealand
4. Latin America
4.1 Brazil
4.2 Mexico
4.3 Argentina
5. Middle East & Africa
5.1 Saudi Arabia
5.2 UAE
5.3 South Africa

All the Key players have been covered from 3 Viewpoints:

• Overview
• Recent Development
• Revenue Analysis

Company Analysis:

1. llumina
2. Abbott Laboratories
3. Thermo Fisher Scientific, Inc.
4. QIAGEN N.V.
5. Roche Holding AG.
6. Sanofi S.A.
7. Agilent Technologies
8. bioMérieux.